Full-Life Technologies to acquire Focus-X Therapeutics
pharmafile | November 29, 2022 | News story | Sales and Marketing |
Full-Life Technologies, a fully integrated global radiotherapeutics company, has announced that they have agreed to acquire US-based Focus-X Therapeutics.
Focus-X Therapeutics develops targeted radiopharmaceuticals to treat cancer, based on proprietary peptide engineering technology. This technology involves peptide radioglands which precisely deliver alpha or beta emitters to break down cancer cell DNA. It allows for high-quality optimisation of peptide radiogland vectors for key pharmaceutical attributes such as biodistribution, binding affinity, and in vivo stability.
Such optimisation can present challenges to other ligand targeting compounds such as antibodies, however the company has focused on both validated targets and new mechanisms.
Under the terms of the acquisition, Focus-X shareholders are eligible to receive an upfront payment from Full-Life, potential development, regulatory and sales-based milestones of up to $245m and royalties on any commercial sales.
Lanny Sun, Co-founder, Chairman and CEO of Full-Life stated: “The Focus-X acquisition perfectly leverages Full-Life’s radiotechnology and development platform by adding two development ready compounds, including a lead with initial human data, a robust pipeline and world class peptide discovery capabilities.”
“Full-Life’s integrated platforms will provide the manufacturing technology, logistics and clinical development expertise to accelerate development of our compounds as well as expand our discovery efforts. This world class radiopharmaceutical team has enormous potential to develop radiopharmaceutical therapeutics that impact patients worldwide,” continued Fa Liu, PhD, Focus-X’s Co-founder and CEO.
James Spargo
